Truist raised the firm’s price target on Crispr Therapeutics (CRSP) to $120 from $100 and keeps a Buy rating on the shares. The company’s Q4 ...

Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the ...

Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

"The ability to insert therapeutic genetic material into the genome ... at Intellia Therapeutics Inc., he established the discovery team and led efforts to expand the company's CRISPR platform ...

CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%.

Functional genomics involves “applying targeted ... which can assist in the development of novel therapeutics that are highly selective for cancer cells. “Innovative applications of CRISPR, namely ...